［1］ DREWES G,TRINCZEK B,ILLENBERGER S,et al.Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark).A novel protein kinase that regulates tau-microtubule interaction and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262［J］.Biol Chem,1995,270(13):7679-7688.
［2］ MARX A,NUGOOR C,PANNEERSELVAM S,et al.Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases［J］.FASEB J,2010,24(6):1637-1648.
［3］ SHULMAN JM,BENTON R,ST JOHNSTON D.The Drosophila homolog of C.elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole［J］.Cell,2000,101(4):377-388.
［4］ LAPIERRE LA,MANNING EH,MITCHELL KM,et al.Interaction of phosphorylated Rab11-FIP2 with Eps15 regulates apical junction composition［J］.Mol Biol Cell,2017,28(8):1088-1100.
［5］ CHENG HW,HSIAO CT,CHEN YQ,et al.Centrosome guides spatial activation of Rac to control cell polarization and directed cell migration［J］.Life Sci Alliance,2019,2(1):e201800135.
［6］ KUO JC,HAN X,HSIAO CT,et al.Analysis of the myosin-Ⅱ-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation［J］.Nat Cell Biol,2011,13(4):383-393.
［7］ LEI Y,ZHANG R,CAI F.Role of MARK2 in the nervous system and cancer［J］.Cancer Gene Ther,2024,31(4):497-506.
［8］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［9］ HENDRIKS LE,KERR KM,MENIS J,et al.Oncogene-addicted metastatic non-small-cell lung cancer:ESMO Clinical Practice Guideline for diagnosis,treatment and follow-up［J］.Ann Oncol,2023,34(4):339-357.
［10］ HUBAUX R,THU KL,VUCIC EA，et al.Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer［J］.Int J Cancer,2015,137(9):2072-2082.
［11］ MARSHALL EA,NG KW,ANDERSON C,et al.Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer［J］.Genom Data,2015,6:145-148.
［12］ NATARAJAN SR,PONNUSAMY L,MANOHARAN R.MARK2/4 promotes Warburg effect and cell growth in non-small cell lung carcinoma through the AMPKα1/mTOR/HIF-1α signaling pathway［J］.Biochim Biophys Acta Mol Cell Res,2022,1869(7):119242.
［13］ SIEGEL R,MILLER K,WAGLE N,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
［14］ PONNUSAMY L,NATARAJAN SR,MANOHARAN R.MARK2 potentiate aerobic glycolysis-mediated cell growth in breast cancer through regulating mTOR/HIF-1α and p53 pathways［J］.J Cell Biochem,2022,123(4):759-771.
［15］ ZHOU Y,NIU W,LUO Y,et al.p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53［J］.Cancer Sci,2019,110(3):939-949.
［16］ 李会琴,吴欣爱,董文杰,等.MARK2在肝癌中的表达及其对肝癌细胞迁移的影响［J］.中国癌症杂志,2018,28(10):733-739.
LI HQ,WU XA,DONG WJ,et al.Expression of MARK2 in hepatocellular carcinoma and its effect on the migration of hepatocellular carcinoma cells［J］.China Oncology,2018,28(10):733-739.
［17］ XU G,GE Y,TAO X,et al.MARK2 inhibits the growth of HeLa cells through AMPK and reverses epithelial-mesenchymal transition［J］.Oncol Rep,2017,38(1):237-244.
［18］ 戈应刚,许舸,高青,等.MARK2基因协同调控HeLa细胞极性与增殖的机制研究［J］.重庆医科大学学报,2017,42(11):1483-1487.
GE YG,XU G,GAO Q,et al.MARK2 regulates cell polarity and cell proliferation in HeLa cells［J］.Journal of Chongqing Medical University,2017,42(11):1483-1487.
［19］ KHERA N,RAJKUMAR AS,ALKURDI KAM,et al.Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells［J］.Mol Cancer,2023,22(1):146.
［20］ 许良.微管亲和调节激酶2对骨肉瘤干细胞顺铂耐药性及骨肉瘤细胞发生发展的作用及机制研究［D］.济南：山东大学,2020.
XU L.The role and mechanism of microtubule affinity regulated kinase 2 on cisplatin resistance of osteosarcoma stem cells and development of osteosarcoma cells［D］.Jinan:Shandong University,2020.
［21］ WEI X,XU L,JEDDO SF,et al.MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells［J］.Am J Transl Res,2020,12(5):1807-1823.
［22］ XU L,SUN Z,WEI X,et al.The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair［J］.J Bone Oncol,2020,23:100290.
［23］ PASAPERA AM,HEISSLER SM,ETO M,et al.MARK2 regulates directed cell migration through modulation of myosin Ⅱ contractility and focal adhesion organization［J］.Curr Biol,2022,32(12):2704-2718.
［24］ KOLBEINSSON HM,CHANDANA S,WRIGHT GP,et al.Pancreatic cancer:A review of current treatment and novel therapies［J］.J Invest Surg,2023,36(1):2129884.
［25］ MOHSENI M,SUN J,LAU A,et al.A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway［J］.Nat Cell Biol,2014,16(1):108-117.
［26］ KWAN J,SCZANIECKA A,HEIDARY ARASH E,et al.DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1/2［J］.Genes Dev,2016,30(24):2696-2709.
［27］ HEIDARY ARASH E,SHIBAN A,SONG S,et al.MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells［J］.EMBO Rep,2017,18(3):420-436.
［28］ ZENG Y,YIN L,ZHOU J,et al.MARK2 regulates chemotherapeutic responses through class Ⅱa HDAC-YAP axis in pancreatic cancer［J］.Oncogene,2022,41(31):3859-3875.